Stock Analiz

Insight Molecular Diagnostics Inc. IMDX

Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026

$2.14Market cap $70M
Open the interactive analysis →

Insight Molecular Diagnostics Inc. (IMDX) is a healthcare company listed in the US with a market value of about $70M. In the twelve months to June 30, 2026 it had revenue of $2M and net income of -$49M, a net margin of -2955.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -77%.

About Insight Molecular Diagnostics

Insight Molecular Diagnostics is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. Revenue went from $1M in 2020 to $4M in 2025, growth of about 27.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 450% over three years (dilution for shareholders). It spends 392% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record2/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S41.9
P/B—
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-44.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)115.6%
Revenue growth (5 yrs, per year)27.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-3367.6%
ROIC (5-yr avg.)-77.4%
Profitable years (of last 10)0
Years paying a dividend1

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2M$4M$2M$2M$958000$2M$1M————
Net income-$49M-$50M-$61M-$28M-$73M-$64M-$30M-$22M-$16M-$19M-$11M
Free cash flow-$31M-$25M-$21M-$24M-$50M-$38M-$27M-$21M-$12M-$13M-$8M
EPS (diluted)$-1.51$-1.65$-4.66$-3.75$-13.25$-0.72$-0.46$-440.00$-420.00$-640.00$-420.00
Net margin-2955.6%-1238.5%-3225.0%-1848.4%-7609.8%-2916.2%-2461.5%————
ROIC———-122.8%-41.5%-68.0%-85.2%-51.6%-260.7%-237.4%-89.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Insight Molecular Diagnostics pay a dividend?

Not currently.

Is Insight Molecular Diagnostics a good stock to buy?

We do not give buy or sell advice. Insight Molecular Diagnostics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.